Stupid question… why would you want to decrease the dopamine in the VTA/mesocortical pathway further by giving an antipsychotic if the negative symptoms being experienced are due to not having enough dopamine already?
Thats a Great question! It's not that you want to decrease the dopamine in mesocortical pathway but when antipsychotics are given. Remember, the antipsychotic doesn't only affect ONE pathway alone but affects ALL the pathways. There's potential to worsen negative symptoms in mesocortical pathway. You might be thinking, are you always going to worsen negative symptoms and if thats the case how do you ever fix schizophrenics with their negative symptoms? So when antipsychotics are given, the positive symptoms go away earlier than negative symptoms do. Negative symptoms take longer to go away and based on assessment, you would decide what antipsychotic to give, first-generation antipsychotics or second-generation antipsychotics. Second-generation antipsychotics are thought to be less likely to cause movement disorder side-effects than typical antipsychotic medicines. This reduced incidence of movement disorder is the main reason why an atypical antipsychotic is often used first-line. Atypicals do, however, have their own risks - in particular, the risk of weight gain. If movement disorder side-effects occur then other drugs may be used to try to counteract them. Hope this helps. :)
Our NEW Patreon Channel is here! Here's the link: www.patreon.com/pmhnp101
your visuals on this with the brain are amazing!
Yes!!! I’m a visual learner and thought it would be helpful for others as well. Thank you Flydelis!
So excited for this to premiere!! Cannot wait!!
Thanks! Looking forward to joining everyone here when it goes live tonight at 8pm.
Can’t wait!!
Thanks! Its goes live tonight at 8pm.
Very Good!
This was so helpful! Wondering if there is a way I can get copies of the slides used in your presentations? thank you!
That was really helpful! Thanks for sharing!
So glad!
Thanks.
Great review.
Thanks for watching!
Stupid question… why would you want to decrease the dopamine in the VTA/mesocortical pathway further by giving an antipsychotic if the negative symptoms being experienced are due to not having enough dopamine already?
Thats a Great question! It's not that you want to decrease the dopamine in mesocortical pathway but when antipsychotics are given. Remember, the antipsychotic doesn't only affect ONE pathway alone but affects ALL the pathways. There's potential to worsen negative symptoms in mesocortical pathway. You might be thinking, are you always going to worsen negative symptoms and if thats the case how do you ever fix schizophrenics with their negative symptoms? So when antipsychotics are given, the positive symptoms go away earlier than negative symptoms do. Negative symptoms take longer to go away and based on assessment, you would decide what antipsychotic to give, first-generation antipsychotics or second-generation antipsychotics. Second-generation antipsychotics are thought to be less likely to cause movement disorder side-effects than typical antipsychotic medicines. This reduced incidence of movement disorder is the main reason why an atypical antipsychotic is often used first-line. Atypicals do, however, have their own risks - in particular, the risk of weight gain. If movement disorder side-effects occur then other drugs may be used to try to counteract them. Hope this helps. :)
@@PMHNP101 How do the negative symptoms go away if we are continuing to lower dopamine levels with the antipsychotic?
@@praisetinungki Can someone answer this please